| Literature DB >> 33587690 |
Amy E Harwood1, Christopher Ja Pugh2, Charles J Steward1, Campbell Menzies1, C Doug Thake1, Tom Cullen1.
Abstract
Intermittent claudication (IC) is associated with impairments in quality of life and walking ability. Heat therapy is an emerging cardiovascular therapy, which may improve walking in patients with IC. We undertook a systematic review to establish current evidence for heat therapy for patients with IC. We searched five databases (Ovid Medline / PubMed, Embase, Scopus / Web of Science, Cochrane Library and Health Technology Assessment Databases). A total of 6751 records were screened with 76 full-text articles assessed for eligibility. We included three randomised control trials and three acute interventions. For chronic interventions, three different heat therapy interventions were used. The 6-minute walk distance significantly improved following whole-body immersion (p = 0.03; ES 0.94, 95% CI: 0.06-1.82), but not after Waon therapy or a water-perfused garment. Ankle-brachial pressure indices were significantly improved following whole-body immersion (p = 0.01; ES 1.10, 95% CI: 0.20-1.99) but not after other therapies. No form of heat therapy demonstrated statistical improvements in quality of life or brachial blood pressure. Acute interventions were characterised by large increases in limb blood flow and core temperature, and transient reductions in blood pressure post-heating. At present there are only three randomised controlled trials assessing heat therapy for patients with IC. Moreover, each of those randomised controlled trials utilised different heat therapies. There is also very limited study of the acute physiological responses to different heat therapy interventions in these populations. Future research should establish appropriate heat therapy protocols and implement more randomised trials to understand its effectiveness. PROSPERO: CRD42020187941.Entities:
Keywords: heat therapy; intermittent claudication; peripheral artery disease (PAD)
Mesh:
Year: 2021 PMID: 33587690 PMCID: PMC8358540 DOI: 10.1177/1358863X20983475
Source DB: PubMed Journal: Vasc Med ISSN: 1358-863X Impact factor: 3.239
Figure 1.Preferred reporting items for systematic reviews and meta-analyses (PRISMA) flow diagram.
PAD, peripheral artery disease.
Summary of RCT intervention findings.
| Study | Sample | Descriptions of intervention | Outcome measures | Main findings |
|---|---|---|---|---|
| Akerman, 201917
| Supervised hot immersion 3–5 × per week at 39°C for progressive duration (w1 = 20 min, w2 = 25 min, w3 = 30 min) to shoulder height. Followed by 15–30 min of warm clothing and calisthenic exercises (3 × per week): seated row, bicep curl, calf press, chest press, lateral raise, leg press, squat and tricep extension (room temp ~21°C). Contractions last for 1 min at 16–20 RPE, then 1 min rest (seating / standing). | 6MWD | Heat therapy: | |
| Monroe, 202023
| Water-circulating garment that pumps hot water (47–50°C) round for 90 min to increase skin temperature to 40°C 3 × per week for 6 weeks. | 6MWD | Heat therapy: | |
| Shinsato, 201022
| Waon dry sauna at 60°C with no hydration pressure. Participants sat in sauna for 15 min and then underwent bed rest with a blanket to keep them warm for 30 min. Undertaken 5 × per week for 6 weeks. | 6MWD | Significant improvement in: |
ABPI, ankle–brachial pressure index; BP, blood pressure; CD34/GAPDH, cluster of differentiation 34 / glyceraldehyde 3-phosphate dehydrogenase; CLI, critical limb ischemia; COPD, chronic obstructive pulmonary disease; CVC, cutaneous vascular conductance; ET-1, endothelin-1; FMD, flow mediated dilatation; HIV, human immune deficiency virus; HRT, hormone replacement therapy; IC, intermittent claudication; IHD, ischemic heart disease; MAP, mean arterial pressure; MI, myocardial infarction; 6MWD, 6-minute walk distance; NIRS, near-infrared spectroscopy; PFWD, pain-free walking distance; PWV, pulse wave velocity; QoL, quality of life; RCT, randomised control trial; RPE, rating of perceived exertion; SEP, supervised exercise programme; SF-36, Short-Form 36; VEGF, vascular endothelial growth factor.
Summary of acute intervention findings.
| Study | Sample | Descriptions of intervention | Outcome measures | Main findings |
|---|---|---|---|---|
| Thomas, 201726
| Water immersion (42°C) up to the waist for 30 min | Popliteal and brachial artery blood flow and shear rate (anterograde, retrograde and total) | Significant improvement in popliteal and brachial artery shear rate and blood flow vs baseline ( | |
| Pellinger, 201925
| Water immersion (40°C) up to a depth of 40 cm for 45 min | Popliteal artery blood flow (velocity and diameter) | Limb blood flow and 6MWD significantly increased after HWI ( | |
| Neff, 201624
| Water-perfused suit up to the waist (48°C) for 90 min | BP and MAP | Skin and core temperature significantly elevated vs control ( |
ABPI, ankle–brachial pressure index; BMI, body mass index; BP, blood pressure; DBP, diastolic blood pressure; ET-1, endothelin-1; HR, heart rate; HWI, hot water immersion; IC, intermittent claudication; IL, interleukin; MAP, mean arterial pressure; MCP, monocyte chemoattractant protein-1; 6MWD, 6-minute walk distance; NOx, nitric oxide; PWV, pulse wave velocity; SBP, systolic blood pressure; sICAM-1, soluble intercellular adhesion molecule-1; sTNFRII, soluble tumour necrosis factor receptor type II; sVCAM-1, soluble vascular cell adhesion molecule-1; TNF-α, tumour necrosis factor-alpha; VEGF, vascular endothelial growth factor.
Figure 2.Risk of bias for included randomised controlled trials.
Symbols indicate risk level: + indicates low risk; ? and ! indicate unclear risk; and - indicates high risk.